Alexander Knuth, M.D.
National Center for Cancer Care and Research
Alexander Knuth, M.D., is the Medical Director and CEO of NCCCR (National Center for Cancer Care and Research) at Hamad Medical Corporation, Doha, Qatar, as of September 2013. Since August 2013, he is professor emeritus of the University of Zurich where he held the chair of Internal Medicine/Oncology since 2003. In 1991, Dr. Knuth established the department of Oncology/Hematology at Krankenhaus Nordwest, an Academic Teaching Hospital of the Johann-Wolfgang Goethe-University in Frankfurt am Main, Germany. He was the chair of this department until his appointment to the University of Zürich.
Dr. Knuth received his medical training at academic institutions in Berlin, Germany, Zürich, Switzerland, and Mainz, Germany, including a clinical and research fellowship at Memorial Sloan Kettering Cancer Center and the Fred Hutchinson Cancer Research Center. His clinical research focus is on cancer immunology and cancer immunotherapy.
His pioneering work in human cancer immunology led to the discovery of multiple human cancer antigens including MAGE, the first candidate of the so-called cancer/testis (CT) family of cancer antigens. Dr. Knuth shared a pivotal role in the development of cancer vaccination strategies with peptides and adjuvants, established immune-monitoring techniques, and discovered tumor escape mechanisms. He holds over 180 patents in the field of cancer immunology and cancer immunotherapy.
He is a founding member of the Academy of Cancer Immunology. He is a co-founder and member of the steering group of the international Cancer Vaccine Collaborative of Cancer Research Institute and Ludwig Cancer Research.
Alexander Knuth is chairman of the scientific advisory board of the Comprehensive Cancer Center Freiburg, Germany, of the University of Freiburg. He serves on multiple scientific advisory boards for academic institutions such as Cancer Research Institute, the German Cancer Research Center, and the National Center for Tumor Diseases (NCT), Heidelberg. From 1994 to 2004, he was member of the scientific review board of Deutsche Krebshilfe (German Cancer Aid), the primary Cancer Charity in Germany. He is a member of the Senate Commission for the Excellence clusters and Collaborative Research Centers of Deutsche Forschungsgemeinschaft (DFG), the government funding body for academic research in Germany.
He is founder and chairman of the board for CT Atlantic, Ltd, a spin-out company of the University of Zurich. The work of the biotechnology firm is based on intellectual property generated in Knuth’s laboratories, such as human derived monoclonal antibodies against CT-antigens for development of innovative strategies in cancer immunotherapy. He serves on editorial boards of multiple scientific journals such as the International Journal of Cancer, Cancer Science, Oncoimmunology, and Cancer Immunology Research.
His early contributions to the discovery of human cancer antigens are covered in A Commotion in the Blood: Life Death, and the Immune System
by Stephen Hall, published by Henry Holt, New York.